

We claim:

1. A method comprising:  
determining whether OX-2/CD200 is upregulated in a subject; and  
administering to the subject a polypeptide that binds to OX-2/CD200 or an OX-2/CD200 receptor.
2. A method as in claim 1 wherein the step of administering a polypeptide comprises administering to the subject an antibody that binds to OX-2/CD200.
3. A method as in claim 1 wherein the step of administering a polypeptide comprises administering to the subject a monoclonal antibody that binds to OX-2/CD200.
4. A method as in claim 1 wherein the step of administering a polypeptide comprises administering to the subject an antibody that binds to an OX-2/CD200 receptor.
5. A method as in claim 1 wherein the step of administering a polypeptide comprises administering to the subject a monoclonal antibody that binds to an OX-2/CD200 receptor.
6. A method as in claim 1 wherein the step of administering a polypeptide comprises administering to the subject a polypeptide comprising one or more amino acid sequences selected from the group consisting of SEQ. ID. NO: 1, SEQ. ID. NO: 2, SEQ. ID. NO: 3, SEQ. ID. NO: 4, SEQ. ID. NO: 5, SEQ. ID. NO: 6, SEQ. ID. NO: 7, SEQ. ID. NO: 8, SEQ. ID. NO: 9, SEQ. ID. NO: 10, SEQ. ID. NO: 11, SEQ. ID. NO: 12, SEQ. ID. NO: 13, SEQ. ID. NO: 14, SEQ. ID. NO: 15, SEQ. ID. NO: 16, SEQ. ID. NO: 17, SEQ. ID. NO: 18, SEQ. ID. NO: 19, SEQ. ID. NO: 20, SEQ. ID. NO: 21, SEQ. ID. NO: 22, SEQ. ID. NO: 23, SEQ. ID. NO: 24, and SEQ. ID. NO: 25.

7. A method of treating a disease state in which OX-2/CD200 is upregulated comprising administering to a subject afflicted with a disease state in which OX-2/CD200 is upregulated a polypeptide that binds to OX-2/CD200 or to an OX-2/CD200 receptor.
8. A method as in claim 7 wherein the step of administering a polypeptide comprises administering to the subject an antibody that binds to OX-2/CD200.
9. A method as in claim 7 wherein the step of administering a polypeptide comprises administering to the subject a monoclonal antibody that binds to OX-2/CD200.
10. A method as in claim 7 wherein the step of administering a polypeptide comprises administering to the subject an antibody that binds to an OX-2/CD200 receptor.
11. A method as in claim 7 wherein the step of administering a polypeptide comprises administering to the subject a monoclonal antibody that binds to an OX-2/CD200 receptor.
12. A method as in claim 7 wherein the step of administering a polypeptide comprises administering to the subject a polypeptide comprising one or more amino acid sequences selected from the group consisting of SEQ. ID. NO: 1, SEQ. ID. NO: 2, SEQ. ID. NO: 3, SEQ. ID. NO: 4, SEQ. ID. NO: 5, SEQ. ID. NO: 6, SEQ. ID. NO: 7, SEQ. ID. NO: 8, SEQ. ID. NO: 9, SEQ. ID. NO: 10, SEQ. ID. NO: 11, SEQ. ID. NO: 12, SEQ. ID. NO: 13, SEQ. ID. NO: 14, SEQ. ID. NO: 15, SEQ. ID. NO: 16, SEQ. ID. NO: 17, SEQ. ID. NO: 18, SEQ. ID. NO: 19, SEQ. ID. NO: 20, SEQ. ID. NO: 21, SEQ. ID. NO: 22, SEQ. ID. NO: 23, SEQ. ID. NO: 24, and SEQ. ID. NO: 25.

13. A method of treating cancer comprising:  
determining whether OX-2/CD200 is upregulated in a subject afflicted with  
cancer; and  
administering to the subject a polypeptide that binds to OX-2/CD200 or an OX-  
2/CD200 receptor.
14. A method as in claim 13 wherein the step of administering a polypeptide  
comprises administering to the subject an antibody that binds to OX-2/CD200.
15. A method as in claim 13 wherein the step of administering a polypeptide  
comprises administering to the subject a monoclonal antibody that binds to OX-  
2/CD200.
16. A method as in claim 13 wherein the step of administering a polypeptide  
comprises administering to the subject an antibody that binds to an OX-2/CD200  
receptor.
17. A method as in claim 13 wherein the step of administering a polypeptide  
comprises administering to the subject a monoclonal antibody that binds to an OX-  
2/CD200 receptor.
18. A method as in claim 13 wherein the step of administering a polypeptide  
comprises administering to the subject a polypeptide comprising one or more amino  
acid sequences selected from the group consisting of SEQ. ID. NO: 1, SEQ. ID. NO: 2,  
SEQ. ID. NO: 3, SEQ. ID. NO: 4, SEQ. ID. NO: 5, SEQ. ID. NO: 6, SEQ. ID. NO: 7,  
SEQ. ID. NO: 8, SEQ. ID. NO: 9, SEQ. ID. NO: 10, SEQ. ID. NO: 11, SEQ. ID. NO: 12,  
SEQ. ID. NO: 13, SEQ. ID. NO: 14, SEQ. ID. NO: 15, SEQ. ID. NO: 16, SEQ. ID. NO:  
17, SEQ. ID. NO: 18, SEQ. ID. NO: 19, SEQ. ID. NO: 20, SEQ. ID. NO: 21, SEQ. ID.  
NO: 22, SEQ. ID. NO: 23, SEQ. ID. NO: 24, and SEQ. ID. NO: 25.

19. A method of treating CLL comprising:
  - determining whether OX-2/CD200 is upregulated in a subject afflicted with CLL;
  - and
  - administering to the subject a polypeptide that binds to OX-2/CD200 or an OX-2/CD200 receptor.
20. A method as in claim 19 wherein the step of administering a polypeptide comprises administering to the subject an antibody that binds to OX-2/CD200.
21. A method as in claim 19 wherein the step of administering a polypeptide comprises administering to the subject a monoclonal antibody that binds to OX-2/CD200.
22. A method as in claim 19 wherein the step of administering a polypeptide comprises administering to the subject an antibody that binds to an OX-2/CD200 receptor.
23. A method as in claim 19 wherein the step of administering a polypeptide comprises administering to the subject a monoclonal antibody that binds to an OX-2/CD200 receptor.
24. A method as in claim 19 wherein the step of administering a polypeptide comprises administering to the subject a polypeptide comprising one or more amino acid sequences selected from the group consisting of SEQ. ID. NO: 1, SEQ. ID. NO: 2, SEQ. ID. NO: 3, SEQ. ID. NO: 4, SEQ. ID. NO: 5, SEQ. ID. NO: 6, SEQ. ID. NO: 7, SEQ. ID. NO: 8, SEQ. ID. NO: 9, SEQ. ID. NO: 10, SEQ. ID. NO: 11, SEQ. ID. NO: 12, SEQ. ID. NO: 13, SEQ. ID. NO: 14, SEQ. ID. NO: 15, SEQ. ID. NO: 16, SEQ. ID. NO: 17, SEQ. ID. NO: 18, SEQ. ID. NO: 19, SEQ. ID. NO: 20, SEQ. ID. NO: 21, SEQ. ID. NO: 22, SEQ. ID. NO: 23, SEQ. ID. NO: 24, and SEQ. ID. NO: 25.